Significant investments

Typically, building a strategic position begins by investing in a private company with development potential and expands at follow-on financing rounds as well as IPOs.

HBM Healthcare is committed to broad diversification according to the following parameters: private and public companies; development phase; therapeutic area; geography; company size (market capitalisation, valuation). Without the Board of Directors' approval, the acquisition value of an investment may not exceed 10 percent of net assets.

Overview as at 30 June 2025

Swixx BioPharma
CHF
215
million
(Fair value CHF 214.7 million / 13.2% of total assets)
more
CHF
186
million
Shanghai Cathay Biotech
(Fair value CHF 185.7 million / 11.7% of total assets)
more
CHF
54
million
Harmony Biosciences
(Fair value 53.8 million / 3.3% of total assets)
more
Neurelis
CHF
45
million
(Fair value CHF 44.6million / 2.7% of net assets)
more
Argenx
CHF
44
million
(Fair value 43.8 million / 2.7% of total assets)
more
Merus
CHF
42
million
(Fair value 41.7 million / 2.6% of total assets)
more
Sai Life Sciences
CHF
33
million
(Fair value CHF 32.6 million / 1.8% of total assets)
more
ArriVent BioPharma
CHF
29
million
(Fair value CHF 28.6 million / 1.8% of total assets)
more
CHF
24
million
Upstream
(Fair value CHF 23.6 million / 1.5% of total assets)
more
CHF
22
million
Fangzhou (Jianke)
(Fair value CHF 22.2 million / 1.4% of net assets)
more